• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21797 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide: benefit assessment according to §35a Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Pomalidomide for relapsed and refractory myeloma]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Pomalidomide combined with dexamethasone in multiple myeloma]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide (multiple myeloma) - Addendum to Commission A19-50]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment))]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide - Addendum to Commission A15-42]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Polysomnography in the diagnosis of sleep-related breathing disorders]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Polymeric diet rich in TGF-β for inflammatory bowel disease in pediatric patients]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2008     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Point-of-care testing in the private sector]
2018     Andalusian Health Technology Assessment Area (AETSA) [Point of care test for differential diagnosis of virus versus bacteria in acute respiratory tract infection]
2009     Committee for New Health Technology Assessment (CNHTA) [POCT(point of care test) prothrombin time]
2009     Committee for New Health Technology Assessment (CNHTA) [PMS2 gene mutation analysis(sequencing)]
2009     Committee for New Health Technology Assessment (CNHTA) [PMP22 exon deletion/duplication test [MLPA]]
2010     Committee for New Health Technology Assessment (CNHTA) [PLP1 gene deletion/duplication test[MLPA]]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Plerixafor (Mozobil) in patients with lymphoma and multiple myeloma]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Platform to analyse RNA, DNA or proteins as biomarkers in the diagnosis, prognosis and assessment of treatments]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in orthopedic diseases]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in maxillofacial surgery]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in fractures and bone pseudoarthrosis]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in diabetic foot ulcers]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in certain orthopedic conditions]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Platelet transfusion in cerebral haemorrhage (PATCH)]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet rich plasma in musculoskeletal conditions]
2007     Andalusian Health Technology Assessment Area (AETSA) [Planned home birth. Current situation in developed countries]
2007     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Place of hyperbaric oxygen therapy in the management of cerebral palsy]
2010     Haute Autorite de sante (HAS) [Place of Breast MRI in the pre-treatment locoregional spread assessment of breast cancer]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pixantrone - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pitolisant (sleep apnoea) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pitolisant (narcolepsy) - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pitolisant (narcolepsy, with or without cataplexy, children and adolescents, 6-17 years) – Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Pirfenidone in pulmonary fibrosis]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pirfenidone - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Pipeline embolization device]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pilot study: conjoint analysis in the indication "hepatitis C"]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pilot study: analytic hierarchy process in the indication "major depression"]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Pilot study to identify and assess obsolete health technologies from emerging technologies identification databases]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Pilot study for understanding the present situation of decorative tattoos]
2009     Committee for New Health Technology Assessment (CNHTA) [PIGA (Phosphatidyl inositol glycan-Class A) mutation analysis]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [PICC line insertion by navigation system and confirmation of the catheter tip by intracavitary electrocardiogram]
2012     Haute Autorite de sante (HAS) [Physiotherapeutic treatment of lymphoedema and shoulder stiffness after breast cancer treatment]
2020     Canary Health Service [Physical exercise intervention in older hospitalized patients for the prevention of functional and cognitive deterioration during hospital admission]
2009     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Physical disease in schizophrenia: systematic review and analysis of hospital records]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Phototherapy and systemic treatment for moderate to severe psoriasis]
2008     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Photoselective vaporization for benign prostatic hyperplasia with KTP (potassium-titanyl-phosphate) laser or GreenLight]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Photopheresis in treatment of steroid-refractory acute graft-versus-host disease]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Photodynamic treatment of subretinal new vessels of choroidal origin in age-related macular degeneration - an HTA]
2020     National Committee for Technology Incorporation (CONITEC) [Photodynamic therapy for non-melanoma skin cancer]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Photodynamic therapy for non-melanocytic skin cancer treatment]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Photodynamic therapy for neovascular age-related macular degeneration]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Photodynamic therapy for lung cancer]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Photodynamic therapy for head and neck cancer treatment]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Photodynamic therapy for colon cancer]
2011     Committee for New Health Technology Assessment (CNHTA) [Photodynamic therapy for bladder, cervix and lung cancer]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Photodynamic therapy for barrett's esophagus and esophageal cancer]
2009     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Photodynamic therapy effectiveness, safety and cost-effectiveness in oesophagus cancer and Barrett oesophagus treatment]
2009     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Photodynamic therapy effectiveness and safety in nonmelanoma skin cancer]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Phlebotonics for venous insufficiency]
2009     Committee for New Health Technology Assessment (CNHTA) [PHEX gene, Mutation[Sequencing]]
2011     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Pharyngeal pH monitoring by Dx-pH measurement system]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pharmacotherapeutic interventions - Evidence report on the S3 guideline "Cannabis-related disorders"]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Pharmacologically-induced voluntary interruption of pregnancy]
2002     Basque Office for Health Technology Assessment (OSTEBA) [Pharmacological treatment of migraines. Qualitative study]
2020     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Pharmacological treatment of common pain conditions in older persons]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Pharmacological treatment for controlled ovarian hyperstimulation in vitro fertilization]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Pharmacological interventions in forensic psychiatry]
2010     Gesundheit Osterreich GmbH (GOeG) [Pharmacological interactions between acetylcholinesterase inhibitors for treatment of dementia and further drugs occurring in patients of advanced age]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Pharmacogenomics bias - systematic distortion of study results by genetic heterogeneity]
2013     The Netherlands Organisation for Health Research and Development (ZonMw) [Pharmacogenetic testing in the clinical setting: is screening for TPMT genotype a cost-effective treatment strategy? The first prospective randomized controlled trial within the Dutch health care system]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Pharmacogenetic test (Neurofarmagen®) to assess the potential response to drugs and adverse effects in patients with neuropsychiatric disorders]
2015     Gesundheit Osterreich GmbH (GOeG) [Pharmaceutical stroke prevention in atrial fibrillation]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Volanesorsen]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tisagenlecleucel (reassessment after expiry: diffuse large B-cell lymphoma)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Pegvaliase]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Mexiletine]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Luspatercept (β-thalassaemia)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Imlifidase (desensitisation in kidney transplantation)]
2016     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Idebenone]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Glycerol phenylbutyrate (New Therapeutic Indication: Urea cycle disorders in infants aged 0 to < 2 months)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Glasdegib (acute myeloid leukaemia (AML), combination with cytarabine (LDAC))]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Givosiran (acute hepatic porphyria, ≥ 12 years)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Fenfluramine (Dravet syndrome, ≥ 2 years)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Burosumab (reassessment after the deadline: hypophosphataemia)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bulevirtide (chronic hepatitis delta virus (HDV) infection)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Betibeglogene autotemcel (β-thalassaemia) (treatment costs)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bedaquiline (new therapeutic indication: multi-drug-resistant pulmonary tuberculosis, 12 to < 18 years)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Axicabtagene ciloleucel]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Axicabtagene ciloleucel (PMBCL)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Autologous anti-CD19-transduced CD3+ cells (mantle cell lymphoma, pretreated patients)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Atidarsagen autotemcel (metachromatic leukodystrophy with biallelic mutation in the ARSA gene)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Amikacin (Mycobacterium avium complex pulmonary infections)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Afamelanotide (Reassessment after the deadline: Phototoxicity in erythropoietic protoporphyria (EPP))]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Phakic intraocular lenses for high-grade myopia]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [PGS for aneuploidies in IVF]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [PET/CT scan for solitary pulmonary nodule and non-small cell lung cancer]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [PET-CT: needs assessment for planning]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [PET-CT in patients with head and neck cancer diagnosis]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [PET-CT evaluative registries in Madrid and Catalunya]